Reuters logo
BRIEF-Anthera announces continuation of simplicity study of sollpura following positive DMC review
December 13, 2016 / 1:48 PM / a year ago

BRIEF-Anthera announces continuation of simplicity study of sollpura following positive DMC review

Dec 13 (Reuters) - Anthera Pharmaceuticals Inc -

* Announces continuation of simplicity study of sollpura following positive DMC review

* DMC was in unanimous agreement “that there are no safety concerns and that study can move forward to enrolling part B”

* Plans to report topline data including efficacy and safety data in Q2 of 2017

* Topline data from phase 3 solution clinical study evaluating efficacy and safety of capsule formulation of sollpura remains on track for the quarter Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below